TherapeuticsMD (TXMD) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
TherapeuticsMD Announces Second Quarter 2021 Financial Results
August 4, 2021 6:50 AM EDT- 2Q21 total net product revenue increased by 17% over 1Q21 to $23 million -
- ANNOVERA® prescription growth supported by improved access to providers and increased telemedicine options for patients -
- Prescriptions for IMVEXXY® grew by 8% over 1Q21, outpacing the VVA market -
- Centers for Medicare and Medicaid Services recommended that ANNOVERA receive its own unique national J-Code that could be live as early as Q421 -
- vitaCare signed new customer and pipeline continues to grow... More
